BioCentury
ARTICLE | Company News

AstraZeneca, University of Cambridge deal

December 8, 2014 8:00 AM UTC

Under a three-year deal, AstraZeneca, its MedImmune LLC biologics unit and the university partnered to research neurodegenerative diseases. The university will contribute its disease biology expertise, experimental models and tissue samples while the pharma and MedImmune will provide access to molecular tools, screening capabilities and drug development expertise to enable target and biomarker discovery and validation. The research will be carried out at MedImmune and university laboratories, and investigators from the parties will work alongside each other. ...